Edward A. Stadtmauer, MD
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Penn Medicine Provider

About me

  • Director, Hematologic Malignancies Clinical/Translational Research, Division of Hematology/Oncology
  • Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Bronx Municipal Hospital - Albert Einstein College
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating

1306 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
so knowledgeable
October 2025
thoroughness
October 2025
listens!!!! good information
October 2025
he has treated other family members with care and compassion.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Stadtmauer is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Shan X, Kuiper R, Ding C, Munshi PN, Stadtmauer EA, Susanibar-Adaniya SP. Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study , Haematologica: 2025


Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2025


Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ. Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis , Eur J Haematol: 2025


Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, Kumar SK, Vogl DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer EA, Pasquini MC. Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702 , Leukemia: 2025


Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Susanibar Adaniya S, Longworth S. Nontuberculous mycobacterial infections following teclistamab in multiple myeloma , Haematologica, 110: 2025,1436-1442


Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies , Nat Med: 2025


Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E. Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma , Bone Marrow Transplant: 2024


Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI. Cytokine-mediated CAR T therapy resistance in AML , Nat Med: 2024


Malek, Ehsan, Kort, Jeries, Metheny, Leland, Fu, Pingfu, Li, Gen, Hari, Parameswaran, Efebera, Yvonne, Callander, Natalie S, Qazilbash, Muzaffar H, Giralt, Sergio, Krishnan, Amrita, Stadtmauer, Edward A, Lazarus, Hillard M Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. , Transplant Cell Ther: 2024


Hasanali ZS, Garfall AL, Burzenski L, Shultz LD, Tang Y, Kadu S, Sheppard NC, Liu W, Dopkin D, Vogl DT, Cohen AD, Waxman AJ, Susanibar-Adaniya SP, Carroll M, Stadtmauer EA, Allman D. Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice , JCI Insight, 9: 2024,e177300